-
Identification of 2,6-Diaminopurine As a Candidate for Hemophilia a Ribosomal Readthrough Therapy
Zhigang Liu et al.,
Blood, 2022
-
Assessment Levels of Factor VIII and IX Inhibitors in Patients with Hemophilia in North West of Iran: What Is the Main Reason of Low Inhibitor Titer and Rate in Our Patients?
Dolatkhah et al.,
Blood
-
Efficacy and Safety of Recombinant Factor IX-FIAV and Bypassing Agents in Thrombin Generation Analyses in Hemophilia A Patient Plasma: The FIVITAS Study
Lorenzo G.R. Romano et al.,
Blood